KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Other Non-Current Liabilities (2016 - 2025)

Astrazeneca (AZN) has 3 years of Other Non-Current Liabilities data on record, last reported at $2.4 billion in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 3560.0% year-over-year to $2.4 billion; the TTM value through Dec 2025 reached $2.4 billion, up 3560.0%, while the annual FY2025 figure was $2.4 billion, 3560.0% up from the prior year.
  • Other Non-Current Liabilities reached $2.4 billion in Q4 2025 per AZN's latest filing, up from $65.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.7 billion in Q4 2023 and bottomed at $65.0 million in Q4 2024.
  • Average Other Non-Current Liabilities over 3 years is $1.7 billion, with a median of $2.4 billion recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 97.56% in 2024, then surged 3560.0% in 2025.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $2.7 billion in 2023, then tumbled by 97.56% to $65.0 million in 2024, then soared by 3560.0% to $2.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $2.4 billion in Q4 2025, $65.0 million in Q4 2024, and $2.7 billion in Q4 2023.